drugset / Trial / NCT04649411

Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

NCT04649411

Phase 3 Withdrawn Keryx Biopharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to evaluate the safety and tolerability of ferric citrate in pediatric participants with iron deficiency anemia (IDA) associated with non-dialysis dependent chronic kidney disease (NDD-CKD).

Timeline

Start
2025-01
Primary completion
2027-01
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric Citrate Unknown Oral